Palazestrant is named as an intervention in 4 current clinical trials in our USA and UK registers. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Olema Pharmaceuticals, Inc. The most-studied condition is Metastatic Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767 · ClinicalTrials.gov ↗ · Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
|
Phase 3 | Recruiting | Olema Pharmaceuticals, Inc. | UK, USA |
|
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193 · ClinicalTrials.gov ↗ · Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1 | Recruiting | Olema Pharmaceuticals, Inc. | USA |
|
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738 · ClinicalTrials.gov ↗ · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
|
Phase 3 | Active, closed | Olema Pharmaceuticals, Inc. | UK, USA |
|
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer
|
Phase 1 | Active, closed | Olema Pharmaceuticals, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Olema Pharmaceuticals, Inc. | 4 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 2 |
| Clinical trials in UK | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our USA and UK registers name Palazestrant as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 2 with sites in USA and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Olema Pharmaceuticals, Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Palazestrant works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Palazestrant works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Palazestrant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.